May 21st 2025
The company made the decision after the FDA requested more vaccine data for the mRNA-1083 vaccine. Moderna plans to resubmit their Biologics License Application (BLA) for the vaccine later this year.
May 21st 2025
FDA leadership says they expect more testing for COVID-19 vaccines and that they generate antibody titers in people in order for vaccines to be considered for approval.
May 19th 2025
The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.
May 15th 2025
Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.
May 7th 2025
In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
COVID-19 Model Shows Travel Restrictions Work, But Testing and Isolation Key
March 16th 2020A mathematical model based on 4 publicly available data sets finds travel restrictions cut the rate of transmission in Wuhan, China. It also found that it likely takes several cases in a given location before the virus sparks an outbreak.
Read More
2 Commerce Drive
Cranbury, NJ 08512